Key Stats for Johnson & Johnson Stock
- Price change for Johnson & Johnson stock in the last 6 months: 16%
- $JNJ Stock Price as of Oct. 23: $264
- 52-Week High: $281
- $JNJ Stock Price Target: $279
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Johnson & Johnson (JNJ) said its experimental prostate cancer pill caused tumors to shrink or disappear in an early-stage trial. The drug is called JNJ-6143 and is taken once a day.
The data were shown at the European Society for Medical Oncology Congress. J&J got the drug through its $3.05 billion deal to buy Halda Therapeutics last year.
The drug works in a new way and kills cancer cells by blocking a protein they need to survive. The trial tested patients with advanced prostate cancer who had already tried several treatments.
Here is what the results showed at the 50-milligram dose:
- 69% of patients with measurable tumors had a confirmed complete or partial response.ed the category as a whole.
- 77% of 31 evaluable patients saw their PSA levels fall by at least 50%. PSA is a blood marker used to track prostate cancer.
- 48% saw PSA levels fall by at least 90%.
Side effects were mostly nausea and higher cholesterol and triglyceride levels, and one patient stopped treatment because of side effects.
A J&J spokesperson said the drug adds a new mechanism of action to its prostate cancer lineup, which was an early-stage trial with a small group, so these results are only a first look.
See analysts’ growth forecasts and price targets for Johnson & Johnson stock (It’s free) >>>
What the Market Is Telling Us About Johnson & Johnson Stock
For Johnson And Johnson stock, this is a pipeline story more than a near-term earnings story. The company said on its Q3 call that it expected data on JNJ-6143 in Q4. Now the data are here.
The call gives useful context. Q3 sales were $25.4 billion, up 6%, and oncology grew about 17%.
The company wants to be the number one oncology company by 2030, and says it can reach more than $50 billion in cancer sales.
There are weak spots too. MedTech grew just 2.5% and fell short of management’s goals. Adjusted earnings per share were $2.59, down 7.5% as management blamed deal costs for much of that drop.
Even so, J&J raised its full-year outlook. It now expects sales of about $100.7 billion at the midpoint.
New cancer drugs are part of that growth plan, which is why early data like this matters for Johnson And Johnson stock.
Investors will want to see larger trials before judging how big the drug could become.
Johnson And Johnson stock may also react to what comes next.
The company will hold an Enterprise Business Review on December 8 and plans to share more on its pipeline and 2027 outlook there.
Estimate a company’s fair value instantly (Free with TIKR) >>>
So what is Johnson & Johnson stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what JNJ stock could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Value Johnson & Johnson for free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
